273 related articles for article (PubMed ID: 26274799)
1. Antiplatelet therapies for secondary stroke prevention: an update on clinical and cost-effectiveness.
Rothlisberger JM; Ovbiagele B
J Comp Eff Res; 2015 Aug; 4(4):377-84. PubMed ID: 26274799
[TBL] [Abstract][Full Text] [Related]
2. Counting the true cost of antiplatelet therapy for stroke prevention.
Morton JA; Newton J; Gray CS
Age Ageing; 2005 May; 34(3):212-4. PubMed ID: 15863405
[No Abstract] [Full Text] [Related]
3. Aspirin plus extended-release dipyridamole or clopidogrel compared with aspirin monotherapy for the prevention of recurrent ischemic stroke: a cost-effectiveness analysis.
Shah H; Gondek K
Clin Ther; 2000 Mar; 22(3):362-70; discussion 360-1. PubMed ID: 10963290
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness analysis of antiplatelet therapy in the prevention of recurrent stroke in the UK. Aspirin, dipyridamole and aspirin-dipyridamole.
Chambers M; Hutton J; Gladman J
Pharmacoeconomics; 1999 Nov; 16(5 Pt 2):577-93. PubMed ID: 10662482
[TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness of antiplatelet agents in secondary stroke prevention: the limits of certainty.
Matchar DB; Samsa GP; Liu S
Value Health; 2005; 8(5):572-80. PubMed ID: 16176495
[TBL] [Abstract][Full Text] [Related]
6. Prevention of secondary stroke and transient ischaemic attack with antiplatelet therapy: the role of the primary care physician [corrected].
Kirshner HS
Int J Clin Pract; 2007 Oct; 61(10):1739-48. PubMed ID: 17877660
[TBL] [Abstract][Full Text] [Related]
7. Aggrenox((R)) versus other pharmacotherapy in preventing recurrent stroke.
Redman AR; Ryan GJ
Expert Opin Pharmacother; 2004 Jan; 5(1):117-23. PubMed ID: 14680441
[TBL] [Abstract][Full Text] [Related]
8. Cost-effectiveness of clopidogrel plus aspirin versus aspirin alone for secondary prevention of cardiovascular events: results from the CHARISMA trial.
Chen J; Bhatt DL; Dunn ES; Shi C; Caro JJ; Mahoney EM; Gabriel S; Jackson JD; Topol EJ; Cohen DJ
Value Health; 2009 Sep; 12(6):872-9. PubMed ID: 19490556
[TBL] [Abstract][Full Text] [Related]
9. Economic evaluation of clopidogrel in acute coronary syndrome patients without ST-segment elevation in Greece: a cost-utility analysis.
Kourlaba G; Fragoulakis V; Maniadakis N
Appl Health Econ Health Policy; 2012 Jul; 10(4):261-71. PubMed ID: 22667992
[TBL] [Abstract][Full Text] [Related]
10. Clopidogrel versus aspirin in patients with atherothrombosis: a CAPRIE-based cost-effectiveness model for Greece.
Kourlaba G; Fragoulakis V; Maniadakis N
Appl Health Econ Health Policy; 2012 Sep; 10(5):331-42. PubMed ID: 22853743
[TBL] [Abstract][Full Text] [Related]
11. Newer antiplatelet therapies in stroke prevention.
Davis SM; Donnan GA
Aust Fam Physician; 2001 Feb; 30(2):129-34. PubMed ID: 11280112
[TBL] [Abstract][Full Text] [Related]
12. Cost-effectiveness of new antiplatelet regimens used as secondary prevention of stroke or transient ischemic attack.
Sarasin FP; Gaspoz JM; Bounameaux H
Arch Intern Med; 2000 Oct; 160(18):2773-8. PubMed ID: 11025787
[TBL] [Abstract][Full Text] [Related]
13. Cost-effectiveness of clopidogrel plus aspirin for stroke prevention in patients with atrial fibrillation in whom warfarin is unsuitable.
Coleman CI; Straznitskas AD; Sobieraj DM; Kluger J; Anglade MW
Am J Cardiol; 2012 Apr; 109(7):1020-5. PubMed ID: 22221944
[TBL] [Abstract][Full Text] [Related]
14. Replacing aspirin and warfarin for secondary stroke prevention: is it worth the costs?
Hankey GJ
Curr Opin Neurol; 2010 Feb; 23(1):65-72. PubMed ID: 19949330
[TBL] [Abstract][Full Text] [Related]
15. Antiplatelet agents for secondary prevention of ischemic stroke.
Majid A; Delanty N; Kantor J
Ann Pharmacother; 2001 Oct; 35(10):1241-7. PubMed ID: 11675854
[TBL] [Abstract][Full Text] [Related]
16. Antiplatelet drugs in cardiovascular prevention: take adverse effects and costs into account.
Prescrire Int; 2000 Jun; 9(47):82-3. PubMed ID: 11010748
[TBL] [Abstract][Full Text] [Related]
17. Dual antiplatelet therapy with clopidogrel and aspirin for secondary stroke prevention.
Wang Y; Chen W; Wang Y
Curr Cardiol Rep; 2015 Oct; 17(10):89. PubMed ID: 26294261
[TBL] [Abstract][Full Text] [Related]
18. [Antiplatelet therapy of secondary stroke prevention after ESPS-2 and CAPRIE].
Alvarez-Sabín J; Montaner-Villalonga J
Rev Neurol; 1999 Oct 16-31; 29(8):780-4. PubMed ID: 10560115
[TBL] [Abstract][Full Text] [Related]
19. Costs and consequences of clopidogrel versus aspirin for secondary prevention of ischaemic events in (high-risk) atherosclerotic patients in Sweden: a lifetime model based on the CAPRIE trial and high-risk CAPRIE subpopulations.
Logman JF; Heeg BM; Herlitz J; van Hout BA
Appl Health Econ Health Policy; 2010; 8(4):251-65. PubMed ID: 20578780
[TBL] [Abstract][Full Text] [Related]
20. Combination antiplatelet agents for secondary prevention of ischemic stroke.
Vande Griend JP; Saseen JJ
Pharmacotherapy; 2008 Oct; 28(10):1233-42. PubMed ID: 18823219
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
